Vertex Pharmaceuticals Incorpor vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
8.4
Buy
Overall
7.3
Buy
Quality
Health
Growth
Valuation
Sentiment
VRTX
High-quality business with 23% return on equity and 33% profit margins.
MRK
High-quality business with 37% return on equity and 28% profit margins.
⚠ earnings contracting 19% year-over-year.
Analyst Consensus
BUY
Target $548.39 (+27.9%)
28 analysts
BUY
Target $129.74 (+17.4%)
27 analysts
Fundamentals
VRTX
MRK
28.0×
Trailing P/E
15.2×
19.7×
Forward P/E
11.4×
32.9%
Profit Margin
28.1%
53.7%
Gross Margin
77.2%
22.5%
ROE
36.9%
9.5%
Revenue Growth
5.0%
32.9%
Earnings Growth
-19.3%
0.37
Beta
0.28
—
Price / Book
—
$109.0B
Market Cap
$273.0B
$363 – $509
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load.